IMS 2023 | Highlights from IMS 2023: integrating multi-omic technologies & understanding resistance
Constantine Mitsiades
• 29 Sep 2023
Constantine Mitsiades, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights from this year’s IMS meeting, commenting on the need to integrate multi-omic technologies with functional genomic assessments in the pre-clinical setting. Additionally, more research must be conducted to better understand mechanisms of resistance to BCMA- and GPRC5D-targeting immunotherapies. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
